Sowell Financial Services LLC Invests $333,000 in United Therapeutics Corporation $UTHR

Key Points

• Sowell Financial Services LLC has invested approximately $333,000 in United Therapeutics Corporation by acquiring 1,160 shares during the 2nd quarter, marking a new stake in the biotechnology company.
• Several analysts have raised their price targets for United Therapeutics, with Cantor Fitzgerald increasing it to $525.00 and Oppenheimer raising it to $575.00, reflecting overall positive sentiment towards the company's stock.
• The company reported a net margin of 40.36% for the last quarter, despite missing earnings estimates, indicating a strong profitability but potential challenges in meeting market expectations.

Sowell Financial Services LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,160 shares of the biotechnology company's stock, valued at approximately $333,000.

Other large investors also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of United Therapeutics in the first quarter worth $313,000. Allianz Asset Management GmbH lifted its stake in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after purchasing an additional 33,254 shares in the last quarter. LPL Financial LLC lifted its stake in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after purchasing an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of United Therapeutics during the first quarter valued at about $227,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on UTHR. Cantor Fitzgerald increased their price target on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. Bank of America increased their target price on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Jefferies Financial Group upped their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Trading Down 3.0%

NASDAQ:UTHR opened at $425.42 on Friday. The company has a market cap of $19.19 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 6.69 and a beta of 0.62. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $442.01. The stock has a fifty day simple moving average of $340.09 and a 200-day simple moving average of $313.84.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the firm posted $5.85 EPS. The business's revenue was up 11.7% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 192,935 shares of company stock valued at $73,905,462. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.